| Institution | Role of Institution | Funding Institution | Reference | Designation | Principal Investigator |
|---|---|---|---|---|---|
| National Projects | |||||
| FFUL | Proponent | FCT | Cooperação Portugal-França ! Programa Pessoa 2022-2023 | Interplay between microglia and T cells at the basis for excessive synaptic pruning associated with Multiple Sclerosis Cognitive Impairment | |
| FFUL | Participant | PT2020 | NORTE-01-0247-FEDER-047213 | SkanABility - Proof of concept for biological activity of cannabinoids and terpenes - cosmeceutical applications | |
| FFUL | Participant | ANI | CENTRO-01-0247-FEDER-072630 | Biopinus - Biotransformação de resina proveniente de Pinus para a produção de biofixadores de pigmentos naturais com aplicação têxtil | |
| FFUL | Proponent | FCT | UID/04138/2020 | Instituto de Investigação do Medicamento | |
| FFUL | Proponent | FCT | PTDC/MED-NEU/29650/2017 | Controlo metabólico da reparação neural pela dieta e microbioma intestinal durante o envelhecimento | |
| FFUL | Proponent | FCT | LISBOA-01-0145-FEDER-029097 |PTDC/MED-FAR/29097/2017 | Fígado gordo não alcoólico: biomarcadores, alvos e terapias emergentes | |
| FFUL | Proponent | FCT | Cooperação Portugal-França | Programa Pessoa | Valorização de blocos sintéticos derivados da biomassa contendo a unidade de furano | |
| FFUL | Participant | PT2020 | LISBOA-01-0145-FEDER-031395 | PTDC/MED-NEU/31395/2017 | Desenvolvimento de uma terapia para uso de exosomas autólogos após modulação de microRNAs em microglia e neurónios-motores recorrendo a modelos animais e humanos de esclerose lateral amiotrófica | |
| FFUL | Participant | PDR 2020 | PDR2020-1.0.1-FEADER-032319 | PinusResina – Estabelecer novas cadeias de valor de transformação e valorização, competitiva e segura, de resina de Pinus em produtos de alto valor acrescentado | |
| FFUL | Participant | PT2020 | LISBOA-01-0145-FEDER-024250 | SAICT-POL/24250/2016 | Assistente virtual para facilitar o autocuidado de pessoas mais velhas com diabetes tipo 2 | |
| FFUL | Participant | PT2020 | PINFRA/22125/2016 | Rede Nacional de Espectrometria de Massa | |
| FFUL | Proponent | PT2020 | SAICTPAC/0019/2015 | Point4PAC – ONCOLOGIA DE PRECISÃO: TERAPIAS E TECNOLOGIAS INOVADORAS | |
| FFUL | Proponent | AstraZeneca | CoviVac - The response of immunocompromised people to COVID-19 vaccine | ||
|
International Projects |
|||||
| FFUL | Participant | Horizon Europe | HORIZON Research and Innovation Actions | halt-RONIN - Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (nonalcoholic steatohepatitis) transition to inform early prevention and treatment strategies | |
| FFUL | Participant | Horizon Europe | HORIZON TMA MSCA Doctoral Networks | OncoProTools - Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment | |
| FFUL | Proponent | La Caixa Foundation | CaixaResearch Validate | Iron-triggered technologies as a novel targeted therapy for cancer | |
| FFUL | Participant | European Comission | EIT Health | i-Days – Innovation Days | |
| FFUL | Proponent | Science for Peace and Security (SPS) NATO Program | SPS G5713 | Biofriendly Decontamination of Chemical Warfare Agents (EnzIL) | |
| FFUL | Proponent | H2020-WIDESPREAD-2018-2020 / H2020-WIDESPREAD-2020-5 | GA 951996 | Straightening Training, Research and Innovation Capacities in the Valorization of Bio-Renewable Resources (Biomass4Synthons) | |
| FFUL | Proponent | European Society of Clinical Microbiology and Infectious Diseases (ESCMID) | ESCMID Research Grant 2018 | Decoding the peptidoglycan patterns associated with beta-lactams hypersusceptibility in drug-resistant Mycobacterium tuberculosis | |
| FFUL | Participant | Comissão Europeia | LIFE-Environment and Resource Efficiency | GA LIFE14 ENV/PT/000739 | Improving current barriers for controlling pharmaceutical compounds in urban wastewater treatment plants | |
| FFUL | Participant | Horizon 2020 | Marie Sklodowska Curie Innovative Actions - Training Networks | H2020-MSCA-ITN-2016_GA_722619 | Bioenergetic remodelling in the pathophysiology and treatment of non-alcoholic fatty liver disease | |
| FFUL | Participant | Horizon 2020 | Innovative Medicines Initiative 2 | H2020-JTI-IMI2-2016-09-two-stage_GA_777377 | Identification and validation of biomarkers for non-alcoholic steatohepatitis (NASH) and across the spectrum of non-alcoholic fatty liver disease (NAFLD) | |
| FFUL | Participant | Horizon 2020 | Marie Sklodowska Curie Actions - Research and Innovation Staff Exchange | H2020-MSCA-RISE-2016_GA_ 734719 | Non-invasive Profiling of Mitochondrial Function in Non-Alcoholic Fatty Liver Disease | |